JP2022500479A5 - - Google Patents

Info

Publication number
JP2022500479A5
JP2022500479A5 JP2021516638A JP2021516638A JP2022500479A5 JP 2022500479 A5 JP2022500479 A5 JP 2022500479A5 JP 2021516638 A JP2021516638 A JP 2021516638A JP 2021516638 A JP2021516638 A JP 2021516638A JP 2022500479 A5 JP2022500479 A5 JP 2022500479A5
Authority
JP
Japan
Prior art keywords
sra141
day
cancer
compound
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021516638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500479A (ja
JP7579781B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2019/019676 external-priority patent/WO2019165473A1/en
Application filed filed Critical
Priority claimed from PCT/US2019/048657 external-priority patent/WO2020068347A1/en
Publication of JP2022500479A publication Critical patent/JP2022500479A/ja
Publication of JP2022500479A5 publication Critical patent/JP2022500479A5/ja
Application granted granted Critical
Publication of JP7579781B2 publication Critical patent/JP7579781B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021516638A 2018-09-24 2019-08-28 Cdc7阻害剤を含む癌の治療方法 Active JP7579781B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862735778P 2018-09-24 2018-09-24
US62/735,778 2018-09-24
US201862760638P 2018-11-13 2018-11-13
US62/760,638 2018-11-13
USPCT/US2019/019676 2019-02-26
PCT/US2019/019676 WO2019165473A1 (en) 2018-02-26 2019-02-26 Methods of treatment of cancer comprising cdc7 inhibitors
PCT/US2019/048657 WO2020068347A1 (en) 2018-09-24 2019-08-28 Methods of treatment of cancer comprising cdc7 inhibitors

Publications (3)

Publication Number Publication Date
JP2022500479A JP2022500479A (ja) 2022-01-04
JP2022500479A5 true JP2022500479A5 (cg-RX-API-DMAC7.html) 2022-09-02
JP7579781B2 JP7579781B2 (ja) 2024-11-08

Family

ID=69952463

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516638A Active JP7579781B2 (ja) 2018-09-24 2019-08-28 Cdc7阻害剤を含む癌の治療方法

Country Status (8)

Country Link
US (1) US12533353B2 (cg-RX-API-DMAC7.html)
EP (1) EP3856352A4 (cg-RX-API-DMAC7.html)
JP (1) JP7579781B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210064252A (cg-RX-API-DMAC7.html)
CN (2) CN113348020A (cg-RX-API-DMAC7.html)
AU (1) AU2019350581B2 (cg-RX-API-DMAC7.html)
CA (1) CA3113621A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020068347A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113621A1 (en) 2018-09-24 2020-04-02 Sierra Oncology, Inc. Methods of treatment of cancer comprising cdc7 inhibitors
KR20220035379A (ko) * 2019-07-19 2022-03-22 다케다 야쿠힌 고교 가부시키가이샤 암 치료를 위한 조합 요법
KR20220054305A (ko) 2019-07-31 2022-05-02 온코어 파마, 인크. 면역 회피성 종양의 치료
WO2022013328A1 (en) * 2020-07-15 2022-01-20 Université Libre de Bruxelles Method for determining sensitivity to an antineoplastic agent
WO2025070603A1 (ja) * 2023-09-27 2025-04-03 カルナバイオサイエンス株式会社 血液がんの新規併用療法
CN117563005A (zh) * 2023-10-26 2024-02-20 浙江大学 一种治疗结直肠癌的药物组合物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO2005014572A1 (en) 2003-08-08 2005-02-17 Pharmacia Italia S.P.A. Pyrimidylpyrrole derivatives active as kinase inhibitors
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
ZA200808966B (en) 2006-03-27 2010-03-31 Nerviano Medical Sciences Srl Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
MX2008013430A (es) 2006-04-19 2009-01-26 Novartis Vaccines & Diagnostic Compuestos de indazol y metodos para la inhibición de cdc7.
FR2907120B1 (fr) 2006-10-12 2013-01-11 Sanofi Aventis Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
JP5284973B2 (ja) 2006-11-28 2013-09-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 三環式インドールおよび(4,5−ジヒドロ)インドール
US8552048B2 (en) * 2006-12-26 2013-10-08 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
EP2120933B1 (en) 2007-02-27 2015-07-08 Nerviano Medical Sciences S.r.l. Isoquinolinopyrrolopyridinones active as kinase inhibitors
AR069869A1 (es) 2007-12-21 2010-02-24 Exelixis Inc Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
WO2010101302A1 (en) 2009-03-05 2010-09-10 Takeda Pharmaceutical Company Limited Thienopyrimidine as cdc7 kinase inhibitors
WO2010122979A1 (ja) 2009-04-20 2010-10-28 Sbiバイオテック株式会社 チアゾリジノン誘導体
CN102471345A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡嗪抑制剂
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
TW201127384A (en) 2009-11-18 2011-08-16 Nerviano Medical Sciences Srl Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
EP3533797B1 (en) 2010-02-17 2023-12-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3338770B1 (en) 2010-03-08 2023-06-07 Sloan-Kettering Institute For Cancer Research Cdc7 kinase inhibitors and uses thereof
US8383623B2 (en) 2010-04-16 2013-02-26 Abbott Laboratories Phthalazin-(2H)-one inhibitors of kinases
MX2012012059A (es) 2010-04-16 2013-03-21 Abbvie Inc Inhibidores de pirrolopirazinona de cinasas.
EP2560971B1 (en) 2010-04-19 2014-04-09 Abbvie Inc. Pyrrolopyridines as inhibitors of kinases
US20120135989A1 (en) 2010-06-29 2012-05-31 Crystalgenomics, Inc. Azaindole derivative
MX344474B (es) 2011-03-31 2016-12-16 Carna Biosciences Inc Nuevos derivados de furanona.
US9974795B2 (en) * 2014-01-31 2018-05-22 Carna Biosciences, Inc. Anticancer agent composition
AU2017354372A1 (en) 2016-11-04 2019-06-20 Carna Biosciences, Inc. Furanone derivates and methods of use thereof
WO2019165473A1 (en) 2018-02-26 2019-08-29 Sierra Oncology, Inc Methods of treatment of cancer comprising cdc7 inhibitors
CA3113621A1 (en) 2018-09-24 2020-04-02 Sierra Oncology, Inc. Methods of treatment of cancer comprising cdc7 inhibitors

Similar Documents

Publication Publication Date Title
US20230398119A1 (en) Combination therapy involving diaryl macrocyclic compounds
JP2019532051A5 (cg-RX-API-DMAC7.html)
RU2589713C2 (ru) Средство, усиливающее действие противоопухолевых средств
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN102740851A (zh) Pi3k抑制剂和mek抑制剂的组合
JP2017526698A5 (cg-RX-API-DMAC7.html)
Bennouna et al. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study
Younes et al. Novel agents in the treatment of Hodgkin lymphoma: biological basis and clinical results
WO2018233620A1 (zh) SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途
JP2023024618A (ja) がんの処置のためのトランス-[テトラクロロビス(1h-インダゾール)ルテネート(iii)]の使用
Ali et al. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
WO2017129094A1 (zh) 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途
WO2021063332A1 (zh) 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途
CN115006397A (zh) 一种预防或治疗肿瘤疾病的药物用途
CN110840892A (zh) 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途
CN111867678B (zh) 治疗黑色素瘤的方法
JP2023505687A (ja) 癌の処置方法
JP2016520665A (ja) Mps−1キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
CN105611934A (zh) 用于治疗化学敏感性或化学耐药性肿瘤的Dendrogenin A和抗肿瘤剂
WO2020239051A1 (zh) Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途
JP2023517671A5 (cg-RX-API-DMAC7.html)
CN106333951A (zh) 一种mTOR激酶抑制剂与MAPK激酶抑制剂的组合物的应用
CA3135916A1 (en) Combined use of a-nor-5a androstane compound drug and anticancer drug
CN115243719A (zh) CTB006与Ponatinib联合应用
CN107137403B (zh) 一种pi3k/mtor抑制剂在制备治疗胰腺癌的药物中的用途